ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1433	National Cancer Institute	Html	en	Genetics of Breast and Gynecologic Cancers (PDQ®)–Health Professional Version	Expert-reviewed information summary about the genetics of breast and gynecologic cancers, including information about specific genes and family cancer syndromes. The summary also contains information about interventions that may influence the risk of developing breast and gynecologic cancers in individuals who may be genetically susceptible to these diseases. Psychosocial issues associated with genetic testing are also discussed.	Pregnancy-associated breast cancer 0.506333 total breast cancer 0.488298 primary breast cancer 0.498056 BRCA1 pathogenic variants 0.493823 Prospective breast cancer 0.487994 Br J Cancer 0.484038 Int J Cancer 0.495039 individual breast cancer 0.489704 cancer risk reduction 0.475227 triple-negative breast cancer 0.516988 breast cancer decline 0.488175 ovarian cancer 0.654478 breast cancer patients 0.493005 postmenopausal breast cancer 0.500017 breast cancer risk. 0.510237 cancer risk assessment 0.501046 Natl Cancer Inst 0.80311 Ovarian Cancer Group 0.476381 BRCA1-associated breast cancer 0.507407 invasive breast cancer 0.506617 endometrial cancer 0.505116 hormone replacement therapy 0.500252 breast cancer prediction 0.489793 et al. 0.567541 BRCA2 mutation carriers 0.531322	women 0.515983 contralateral breast cancer 0.498075 early breast cancer 0.50631 early-onset breast cancer 0.489583 nonpolyposis colorectal cancer 0.483231 breast cancer family 0.518542 breast cancer diagnosis 0.495632 BOADICEA breast cancer 0.48834 PUBMED Abstract 0.498618 pathogenic variants 0.552407 Cancer Res Treat 0.576792 Breast Cancer Treatment 0.508531 epithelial ovarian cancer 0.48165 ovarian cancer risk 0.536184 breast cancer risk 0.765155 Abstract 0.613814 breast cancer survival 0.499805 breast cancer 0.946746 breast cancer mortality 0.506691 Breast cancer cluster 0.487434 family history 0.570688 breast cancer incidence 0.492239 familial breast cancer 0.49066 Breast Cancer Res 0.640001	CLICK HERE
1480	National Cancer Institute	Html	en	Gastric Cancer Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of gastric cancer.	median survival 0.63157 Three-year overall survival 0.637349 postoperative chemotherapy 0.607291 evidence 0.599884 S-1 group 0.532476 United States 0.629181 IIIB gastric cancer 0.571507 gastric cancer resection 0.57432 adjuvant chemoradiation therapy 0.846798 trial 0.61074 Postoperative chemoradiation therapy 0.558554 adjuvant combined modality 0.6554 total gastrectomy 0.60297 3-year OS rate 0.544309 3-year OS rates 0.626301 postoperative combined chemoradiation 0.551401 median follow-up 0.535007 therapy versus surgery 0.546551 chemoradiation therapy group 0.623893 significantly higher likelihood 0.622742 postoperative chemoradiation regimen 0.637796 noncardia gastric cancers 0.63288 surgery-only group 0.537222 relapse-free survival rates 0.794523	3-year OS 0.717532 gastroesophageal junction 0.570534 disease-free survival rate 0.550481 gastric cancer 0.998454 progression-free survival 0.57907 patients 0.884826 Neoadjuvant chemoradiation therapy 0.554541 metastatic gastric cancer 0.697572 curative intent 0.539619 significant survival benefit 0.6365 prospective multi-institution phase 0.543154 surgery-alone arm 0.607016 proximal subtotal gastrectomy 0.57677 perioperative chemotherapy group 0.806838 lymph nodes 0.576141 completely resected stage 0.638305 chemoradiation therapy 0.899775 hazard ratio 0.57654 regional lymph nodes 0.559708 Level 0.600335 chemoradiation therapy versus 0.543268 phase III trial 0.597716 3-year disease-free survival 0.564109	CLICK HERE
1535	National Cancer Institute	Html	en	Hydrazine Sulfate (PDQ®)–Health Professional Version	Expert-reviewed information summary about the use of hydrazine sulfate as a treatment for people with cancer. Note: The information in this summary is no longer being updated and is provided for reference purposes only.	single agent 0.446847 measurable tumor regression 0.444265 hydrazine sulfate group 0.561221 stable disease 0.438607 hydrazine sulfate therapy. 0.512358 advanced nonsmall cell 0.439337 body weight 0.435692 prostate cancer tumors 0.435725 best tumor responses 0.433645 anticancer treatment 0.440366 white blood cells 0.437041 bladder cancer tumors 0.452946 clinical trials 0.508473 cancer information summary 0.434117 clinical drug research 0.432809 placebo group 0.446705 patients 0.531553 FBCa bladder cancer 0.447874 cancer patients 0.442585 hydrazine sulfate therapy 0.539457 complete responses 0.433235 multiple-drug chemotherapy regimen 0.457646 breakdown products 0.436734 human tumor cells 0.434705 radiation therapy 0.432799	anticancer activity 0.483124 hydrazine sulfate research 0.543056 treatment 0.474001 United States 0.450385 hydrazine sulfate administration 0.532876 National Toxicology Program 0.441282 nonsmall cell lung 0.4545 clinical series 0.445474 hydrazine compounds 0.479897 hydrazine analogs 0.451642 National Cancer Institute 0.447177 tumor growth 0.446716 partial responses 0.440765 Cancer Treatment Group 0.438635 hydrazine sulfate blocks 0.527938 hydrazine antidepressants 0.434523 enhanced antitumor activity 0.43882 advanced cancer 0.436974 animal studies 0.436395 hydrazine sulfate 0.995392 Hydrazine administration 0.434303 cell lung cancer 0.443379 objective tumor response 0.459617 clinical studies 0.444539	CLICK HERE
1703	National Cancer Institute	Html	en	Tumor Grade	A fact sheet that discusses tumor grade and its role in prognosis. Explains concepts like normal cell biology and cell differentiation.	Gleason score 0.401724 NCI fact sheet 0.404685 lower grade 0.405507 tissue organization 0.400496 better prognosis 0.354968 tumor tissue 0.703634 type-specific grading systems 0.412132 tumor type 0.491464 cancer cells 0.405656 biopsied tissue 0.413701 Gleason scores 0.355221 primary brain tumors 0.42294 tumor size 0.501863 abnormal-looking cells 0.400459 Nottingham grading 0.360235 higher-grade cancer 0.364598 tumor cells 0.631844 normal cells 0.49423 nearby lymph nodes 0.408457 tumor grade 0.785451 regional lymph node 0.409603 secondary pattern 0.388809 breast tumors 0.384185 Scarff-Bloom-Richardson grading 0.361738	normal tissue structures 0.487646 primary pattern 0.353415 microscopic examination 0.353649 breast cancer 0.39308 biopsy samples 0.354483 Staging page 0.357155 microscopic appearance 0.359178 different types 0.358151 tumors 0.490957 prostate cancer 0.440387 cancer staging 0.368981 slower rate 0.360886 American Joint Committee 0.39399 tumor 0.981653 tumor grades 0.501473 common tissue pattern 0.44497 cancer 0.557882 total score 0.354108 soft tissue sarcoma 0.443518 prostate cancers 0.367392 Gleason scoring 0.35738 tumor tissue look 0.635152 cancer stage 0.457333	CLICK HERE
1806	National Cancer Institute	Html	es	Tratamiento del cáncer de estómago (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer de estómago.	after d2 gastrectomy 0.313513 gastrectomía d2 0.31496 Cunningham D 0.34388 Macdonald JS 0.318723 Chemoradiotherapy after surgery 0.344328 randomised controlled 0.319618 combined modality therapy 0.360634 mejoría significativa 0.31176 Stenning SP 0.310838 intergroup trial calgb 0.31542 Postoperative adjuvant chemoradiation 0.322032 after ci 5-fu 0.317294 fase iii 0.364462 Estados Unidos 0.347269 with s-1 0.314235 randomized trial comparing 0.314288 quimiorradioterapia posoperatoria 0.360835 ensayo rtog-9904 0.324678 patients with 0.484752 adyuvante versus tasa 0.360686 supportive care 0.325372 Clinical Oncology 0.311085 Perioperative chemotherapy versus 0.334581 chemotherapy plus best 0.312401 Smalley SR 0.318682	with surgery 0.339493 Ajani JA 0.354002 or gastroesophageal junction 0.340588 ensayo swog-s0425 0.324881 Allum WH 0.311046 quimiorradioterapia adyuvante versus 0.364135 estadio ib 0.338006 gastrectomía curativa d2 0.319296 Van Cutsem E 0.313883 Benedetti J 0.318647 quimioterapia perioperatoria 0.352185 gastric carcinoma 0.325701 gastric cancer 0.935626 Clin Oncol 0.612714 or gastro-oesophageal junction 0.317111 trial comparing 0.314461 supportive care with 0.324232 Winter K 0.319459 Gastric Cancer Study 0.317632 chemotherapy versus surgery 0.338116 grupo s-1 0.317965 Okawara GS 0.319919 care with best 0.314996 quimioterapia posoperatoria 0.31518	CLICK HERE
1943	National Cancer Institute	Html	es	Síndromes cardiopulmonares (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca de las afecciones comunes que producen síntomas en el tórax. Los síndromes cardiopulmonares que se exponen en este sumario son la disnea relacionada con el cáncer, el derrame pleural maligno, el derrame pericárdico y el síndrome de la vena cava superior.	pleural catheter 0.17861 Ripamonti C 0.130559 dificultad respiratoria 0.26023 malignant effusion 0.115362 lung cancer 0.190962 Sin embargo 0.114284 end-of-life patients with 0.119385 indwelling pleural catheter 0.162022 Dudgeon DJ 0.13043 fármacos pleurales esclerosantes 0.112004 disfunción muscular respiratoria 0.121219 Hematol Oncol Clin 0.143013 hypoxemic patients with 0.118489 patients receiving chemotherapy 0.111162 Cancer Organisation Thoracic 0.117844 antitusivos opioides 0.112496 recurrent symptomatic malignant 0.110714 patients with 0.625852 insuficiencia cardiaca 0.134239 Pain Symptom Manage 0.478956 randomized controlled 0.112081 pleural fluid 0.136904 Cancer Dyspnea Scale 0.146703 Moroni M 0.110841 Care Cancer 0.128094	pleural catheter vs 0.135869 Physiol Neurobiol 0.116436 as symptomatic treatment 0.110943 derrame maligno fracasa 0.114534 obstructiva crónica 0.135859 vías respiratorias 0.205286 tunnelled pleural catheter 0.139919 tos crónica causa 0.111919 prospective randomized 0.110614 pleural effusions with 0.149859 Intern Med 0.132242 Clin Oncol 0.11762 Med Pediatr Oncol 0.111608 Clin North Am 0.136363 Bruera E 0.203018 systematic review 0.116364 Oncol Clin North 0.140711 American Thoracic Society 0.114142 as palliative treatment 0.110799 malignant pleural effusions 0.900896 Crit Care Med 0.171232 symptomatic malignant 0.122652 alone versus 0.11566 compared with 0.110951	CLICK HERE
2082	National Cancer Institute	Html	en	Cancer Clusters	A fact sheet that describes what constitutes a cancer cluster and the process for reporting and investigating suspected clusters.	major risk factor 0.385962 specific environmental hazards 0.38074 rare cancer 0.409989 website uses data 0.380594 cancer trends 0.398646 individual cancer clusters 0.469731 number 0.405815 investigators 0.393508 Health Hazard Evaluation 0.380995 Disease Control 0.519415 Health Consultations page 0.381331 cancer cluster 0.895701 cancer clusters 0.841764 National Center 0.381056 ATSDR regional offices 0.380684 different geographic area 0.38274 cluster investigations 0.411002 true cancer clusters 0.482566 public health assessments 0.472612 statistically significant difference 0.384068 vinyl chloride 0.380035 specific cancer type 0.434002 primary cancer 0.413707 U.S. Census Bureau 0.37492 specific hazardous substances 0.37613	different cancer types 0.429181 state health department 0.450442 total number 0.385248 cancer cases 0.749447 health departments 0.457783 NCI analyze variations 0.380726 local health departments 0.450682 geographic area 0.518161 specific geographic area 0.389344 health surveillance programs 0.382617 people 0.378106 epidemiologic study 0.378396 agency gathers information 0.381997 statistically significant excess 0.455543 secondary cancer 0.393665 cancer 0.954313 state cancer registries 0.443891 cancer cluster—that 0.391887 Disease Registry 0.381886 specific time period 0.392616 Toxic Substances 0.380998 cancer death rates 0.436653 cancer incidence 0.401099 Cancer Mortality Maps 0.435229	CLICK HERE
3580	National Cancer Institute	Html	en	Cancer Genomics Research	Investigating the genetic foundations of cancer has improved our understanding of cancer biology and led to better prevention, diagnosis and treatment methods.	potential cancer genes 0.58754 multiple genomic techniques 0.659582 previous genomic studies 0.697319 cancer genomics 0.705134 clinical trials 0.615766 genomic data 0.812653 Genomic tools 0.615952 genomic signatures 0.587963 genomic characterization 0.591197 NCI’s Division 0.582338 genomic information 0.620002 genomic changes 0.698716 Genomic Data Commons 0.677909 NCI-generated genomic datasets 0.64782 standard cancer treatments 0.600357 cancer genome 0.653485 nci genomic data 0.792126 rare cancer subtypes 0.618402 human cancer 0.596543 cancers 0.577123 cancer genomes 0.733233 Cancer Driver Discovery 0.592638 Human Models Cancer 0.601 genomic basis 0.598972 cancer genomic data 0.759195	raw genomic data 0.677768 new cancer models 0.609201 cancer cells 0.581921 cancer genome studies 0.638148 cancer cell lines 0.586373 cancer genomics research 0.701055 initial genomic discoveries 0.63816 Cancer Genome Characterization 0.60378 lung cancer trials 0.58967 genomic subtypes 0.604215 studies cancer genomes 0.636536 Cancer Genomics Cloud 0.591583 genetic alterations 0.63917 Cancer Genome Atlas 0.60256 cancer development 0.593441 genomic insights 0.591156 DCEG Cancer Genomics 0.589882 diverse cancer genomics 0.601997 genomic methods 0.620776 genomic traits 0.649401 genomic studies 0.746705 cancer 0.914614 genomic data sharing 0.682873 Cancer Treatment Discovery 0.59833	CLICK HERE
16825	National Cancer Institute	Html	en	NCI's Genome Characterization Pipeline	The Genome Characterization Pipeline, run by NCI’s Center for Cancer Genomics, transforms cancer tissue samples into rich genomic datasets that are shared with the research community.	DNA mutation drivers 0.542472 CCG Genomic Data 0.762494 collaborative effort 0.483957 GDC 0.485667 standardized workflow 0.488583 clinical data 0.512601 Working Groups 0.474461 future research 0.474579 Nationwide Children 0.482385 clinical trials 0.4849 Data Analysis Network 0.766186 big data 0.506113 Genomic Data Commons 0.920724 rich data 0.497819 normal tissue 0.486161 CCG pipeline 0.580522 clinical datasets 0.491928 BCR 0.476542 genomic characterization techniques 0.643779 multi-omics data 0.504906 community oncology groups 0.554099 NCI’s Center 0.495612 diverse team 0.474615 expandable data sharing 0.563688 wide range 0.476766	facilitate precision oncology 0.534807 cancer research community 0.569169 United States 0.565759 CCG’s Analysis 0.590169 Tumor tissues 0.508861 Hospital processes 0.481423 rigorous quality standards 0.551886 CCG’s Genomic 0.671044 Data Access Processes 0.55821 Genome Characterization Centers 0.857246 Genome Characterization Pipeline 0.608208 CCG studies 0.604302 GDAN shares 0.480133 raw output 0.475322 CCG partners 0.607468 tumor tissue samples 0.559731 research teams 0.490873 CCG 0.76836 rich cancer 0.489758 Cancer Genomics 0.492347 novel analyses 0.47767 NCI Genomic Data 0.636969 Genomic Data Analysis 0.825105 Biospecimen Core Resource 0.713807	CLICK HERE
17279	National Cancer Institute	Html	es	Planes para atender un cáncer avanzado	Una planificación cuidadosa reducirá el peso que enfrentará su familia más adelante. La planificación puede incluir aspectos económicos y legales, pero como verá, también puede ser una forma de celebrar su vida y de darle significado.	tensiones. Algunas personas 0.876955		CLICK HERE